|
|
|
|
|
Legal status
Patent not validated
| (51) | INT.CL. | A61K 38/19 | |
| A61K 31/00 | |||
| C12N 15/86 | |||
| G01N 33/574 |
| (11) | Number of the document | 2806883 |
| (13) | Kind of document | T |
| (96) | European patent application number | 13706770.8 |
| Date of filing the European patent application | 2013-01-25 | |
| (97) | Date of publication of the European application | 2014-12-03 |
| (45) | Date of publication and mention of the grant of the patent | 2019-04-24 |
| (46) | Date of publication of the claims translation |
| (86) | Number | PCT/US2013/023304 |
| Date | 2013-01-25 |
| (87) | Number | WO 2013/112942 |
| Date | 2013-08-01 |
| (30) | Number | Date | Country code |
| 201261590441 P | 2012-01-25 | US | |
| 201261637191 P | 2012-04-23 | US |
| (72) |
TUFARO, Frank, US
CONRAD, Charles, US
FUEYO-MARGARETO, Juan, US
LANG, Frederick, US
GOMEZ-MANZANO, Candelaria, US
YUNG, W.k., Alfred, US
HEIMBERGER, Amy, US
|
| (73) |
Board of Regents, The University of Texas System,
210 West 7th Street, Austin, TX 78701,
US
DNAtrix, Inc., 2450 Holcombe Boulevard Suite X+200, Houston, TX 77021, US |
| (54) | BIOMARKERS AND COMBINATION THERAPIES USING ONCOLYTIC VIRUS AND IMMUNOMODULATION |
| BIOMARKERS AND COMBINATION THERAPIES USING ONCOLYTIC VIRUS AND IMMUNOMODULATION |